<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00622323</url>
  </required_header>
  <id_info>
    <org_study_id>H8O-PH-B006</org_study_id>
    <secondary_id>H8O-PH-B006</secondary_id>
    <nct_id>NCT00622323</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients</brief_title>
  <official_title>Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, non-interventional, post marketing surveillance study to determine the
      proportion of patients experiencing an adverse event and a list of the experienced adverse
      events, serious and non-serious, that would occur among Filipino patients with type 2
      diabetes mellitus who are treated with exenatide who are taking metformin, a sulfonylurea or
      a combination of metformin and a sulfonylurea but have not achieved adequate glycemic
      control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the proportion of patients experiencing an adverse event and a list of the experienced adverse events, that would occur among Filipino patients with type 2 diabetes and inadequate glycemic control treated with exenatide</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the change from baseline to endpoint in HbA1c and body weight of Filipino patients with type 2 diabetes mellitus treated with exenatide who are taking metformin and/or a sulfonylurea but have not achieved adequate glycemic control.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">41</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female patients at least 18 years of age and diagnosed with type 2 diabetes
        mellitus treated in an ambulatory care setting and who are taking metformin, a
        sulfonylurea, or a combination of metformin and sulfonylurea, but have not achieved
        adequate glycemic control. Female patients eligible of becoming pregnant are required to
        have some form of contraception while participating in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  are male or female outpatients at least 18 years of age

          -  provide written consent to the release of their data after being informed of the study

          -  diagnosed with type 2 diabetes mellitus and are taking metformin, or a sulfonylurea or
             both

          -  are reliable, and agree to keep all appointments for clinic visits, complete tests and
             procedures as may be required by the attending physician in the course of routine
             clinical care

          -  are treated with exenatide according to the approved Product Insert, as prescribed by
             the investigator in the routine care of the patient

        Exclusion Criteria:

          -  are simultaneously participating in a different study that includes a treatment
             intervention and/or an investigational drug.

          -  are currently taking insulin.

          -  are pregnant or have intentions of becoming pregnant within the duration of the study.

          -  are the investigators or their immediate families. Immediate family is defined as the
             investigator's spouse, parents, natural or legally adopted child (including stepchild
             living in the investigator's household), grandparents, or grandchild. Employees of
             investigators are also not eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paranaque City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pasig City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taytay</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com/</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2008</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>exenatide</keyword>
  <keyword>metformin</keyword>
  <keyword>sulfonylurea</keyword>
  <keyword>Byetta</keyword>
  <keyword>Amylin</keyword>
  <keyword>Lilly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

